CG
GALT icon

Cutler Group’s Galectin Therapeutics GALT Stock Holding History

Cutler Group’s Portfolio GALT Stock Details GALT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2016
Q3 		– Sell
-1,000
Closed -$1K – 6899
2016
Q2 		$1K Hold
1,000
– – ﹤0.01% 6063
2016
Q1 		$1K Buy
+1,000
New +$1.34K ﹤0.01% 5973

Other funds holding GALT

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Osaic Holdings
Osaic Holdings Scottsdale, Arizona $68.3B AUM 20.5% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
GWM
Geneos Wealth Management Englewood, Colorado $4.31B AUM 18.36% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
CCB
Cutter & Co Brokerage Ballwin, Missouri $423M AUM 15.02% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Cutler Group's GALT Position: Q4 2021 in Review

Cutler Group sold out of Galectin Therapeutics (GALT) in Q4 2021, closing a stake of 3,500 shares — an estimated $9.99K sold.

Cutler Group first reported a position in GALT in Q4 2015 and held it in 10 quarters. The position peaked at $13K in Q3 2021. 55 funds tracked by Wall St. Rank hold GALT as of Q4 2021.

  • Cutler Group reported no remaining Galectin Therapeutics position as of Q4 2021 after selling out during the quarter.
  • Cutler Group sold 3,500 Galectin Therapeutics shares in Q4 2021, an estimated $9.99K.
  • Cutler Group first reported a position in Galectin Therapeutics in Q4 2015 and held it in 10 quarters.
  • Cutler Group's Galectin Therapeutics position peaked at $13K in Q3 2021.
  • 55 funds tracked by Wall St. Rank held Galectin Therapeutics as of Q4 2021.

Based on Cutler Group's 13F filing for Q4 2021, filed 18 Jan 2022.